CAJ | 학술논문

Objective: To evaluate the therapeutic efficacy of injecting highly agglutinative staphylococcin (HASL) and cisplatin into pericardial cavity of lung cancer patients with pericardial effusion.Methods: 81 patients were randomized into two groups:45 in the experimental group (HASL and Cisplatin) and 36 in the control group (Cisplatin).At first pericardial effusion was drained out from a intrapericardial catheter and then different drugs were infused,respectively.24 h after perfusion the draining continued again until drainage quantity was less than 30 mL every day.The draining lasted 10-15 days.Results: The response rate was 91.1% for the experimental group and 80.6% for the control group.There was no significant difference between the two groups(P＞0.05).The complete remission was 77.8% for the experimental group and 52.8% for the control group,which was statistically significant difference (P＜0.05).The adverse effects were myelosuppression and nausea and vomiting,which were 35.6% and 40.0% in the experimental group and 72.2% and 66.7% in the control group,respectively (P＜0.01,P＜0.05).Conclusion: Injecting HASL and cisplatin into pericardial cavity may be a better way to control pericardial effusion of lung cancer.